Definium Therapeutics, Inc. (DFTX)
| Market Cap | 4.88B +398.5% |
| Revenue (ttm) | n/a |
| Net Income | -353.79M |
| EPS | -3.48 |
| Shares Out | 134.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,076,283 |
| Open | 37.24 |
| Previous Close | 37.96 |
| Day's Range | 35.87 - 37.95 |
| 52-Week Range | 10.47 - 49.70 |
| Beta | 2.19 |
| Analysts | Strong Buy |
| Price Target | 72.56 (+99.73%) |
| Earnings Date | Nov 9, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $72.56, which is an increase of 99.73% from the latest price.
News
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Definium Therapeutics (DFTX) with an Overweight rating and $84 price target The company’s lead asset DT120 ODT is being developed as a treatment for various neuropsychia...
Definium Therapeutics Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Phase III trials of DT120 in GAD and MDD showed robust efficacy and benign safety, with single treatments yielding significant improvements and high response/remission rates. Open-label retreatment in Part B led to 60–70% mild/remission rates, and regulatory discussions are ongoing for potential dual indication filing.
Definium Therapeutics Slides: Corporate presentation
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Definium Therapeutics price target raised to $78 from $64 at Canaccord
Canaccord raised the firm’s price target on Definium Therapeutics (DFTX) to $78 from $64 and keeps a Buy rating on the shares. The firm updated its model following its stellar…
Definium Therapeutics price target raised to $79 from $75 at Baird
Baird raised the firm’s price target on Definium Therapeutics (DFTX) to $79 from $75 and keeps an Outperform rating on the shares. The fim updated its model following solid Panorama…
Definium Therapeutics price target raised to $75 from $70 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $75 from $70 and keeps an Outperform rating on the shares. The firm sees the “positive” Phase 3 Panorama…
Definium Therapeutics price target raised to $91 from $75 at BofA
BofA raised the firm’s price target on Definium Therapeutics (DFTX) to $91 from $75 and keeps a Buy rating on the shares. Definium reported positive topline results from the Phase…
First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip.
Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.
Definium Therapeutics Transcript: Study result
Panorama phase III results show DT120 100 mcg delivers rapid, robust, and durable efficacy in GAD, with a strong safety profile and consistent benefit across subgroups. Long-term data support sustained response and benefit from intermittent retreatment. NDA filing is planned for 2027.
Definium Therapeutics Press release: Study result
Definium Therapeutics issued a press release on September 14, 2026, disclosing material business information to investors.
Definium Therapeutics Slides: Study result
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Definium says Phase 3 Panorama study met primary, secondary efficacy endpoints
Definium Therapeutics (DFTX) announced topline results from Panorama, the Company’s second Phase 3 study of DT120 Orally Disintegrating Tablet in adults with generalized anxiety disorder. This is the ...
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics announce six poster presentations at Psych Congress
Definium Therapeutics (DFTX) announced six poster presentations at the Psych Congress taking place September 15 through 19 in New Orleans, LA. “This year at Psych Congress, we will share clinical…
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics receives Breakthrough Therapy designation for DT120 ODT
Definium Therapeutics (DFTX) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation for DT120 Orally Disintegrating Tablet, ODT. The designation was su...
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics, Inc. put volume heavy and directionally bearish
Bearish flow noted in Definium Therapeutics (DFTX), Inc. with 1,463 puts trading, or 3x expected. Most active are Oct-26 37 puts and Oct-26 49 calls, with total volume in those…
Definium Therapeutics, Inc. put volume heavy and directionally bearish
Bearish flow noted in Definium Therapeutics (DFTX), Inc. with 2,903 puts trading, or 6x expected. Most active are Oct-26 37 puts and Oct-26 50 calls, with total volume in those…
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics initiated with a Buy at BofA
BofA analyst Tazeen Ahmad initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $75 price target The company’s lead asset, DT120 – LSD – is in pivotal studies…
Definium Therapeutics announces results from Phase 3 study of DT120
Definium Therapeutics (DFTX) announced positive topline results from Voyage, its first Phase 3 study of DT120 Orally Disintegrating Tablet, ODT, 100 microgram in adults with generalized anxiety disord...
Definium Therapeutics price target raised to $70 from $60 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $70 from $60 and keeps an Outperform rating on the shares.